| Id: | acc4565 |
| Group: | 1sens |
| Protein: | NF-kappaB p65 |
| Gene Symbol: | Rela |
| Protein Id: | Q04207 |
| Protein Name: | TF65_MOUSE |
| PTM: | phosphorylation |
| Site: | Ser536 |
| Site Sequence: | SGDEDFSSIADMDFSALLSQI |
| Disease Category: | Endocrine and metabolic diseases |
| Disease: | Diabetes Mellitus |
| Disease Subtype: | Diabetic Nephropathy |
| Disease Cellline: | |
| Disease Info: | |
| Drug: | AM095 |
| Drug Info: | AM095 is a drug that may have specific pharmacological effects and applications in medical research or treatment. |
| Effect: | modulate |
| Effect Info: | AM095 treatment inhibits the expression of LPA-induced pro-inflammatory cytokines and fibrotic factors by downregulating phosphorylated NFκBp65 and c-Jun N-terminal kinase (JNK) in vitro and in the kidneys of STZ-induced diabetic mice. |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 30763641 |
| Sentence Index: | 30763641_0 |
| Sentence: | "Lysophosphatidic acid receptor 1 inhibitor, AM095, attenuates diabetic nephropathy in mice by downregulation of TLR4/NF-kappaB signaling and NADPH oxidase." |
Sequence & Structure:
MDDLFPLIFPSEPAQASGPYVEIIEQPKQRGMRFRYKCEGRSAGSIPGERSTDTTKTHPTIKINGYTGPGTVRISLVTKDPPHRPHPHELVGKDCRDGYYEADLCPDRSIHSFQNLGIQCVKKRDLEQAISQRIQTNNNPFHVPIEEQRGDYDLNAVRLCFQVTVRDPAGRPLLLTPVLSHPIFDNRAPNTAELKICRVNRNSGSCLGGDEIFLLCDKVQKEDIEVYFTGPGWEARGSFSQADVHRQVAIVFRTPPYADPSLQAPVRVSMQLRRPSDRELSEPMEFQYLPDTDDRHRIEEKRKRTYETFKSIMKKSPFNGPTEPRPPTRRIAVPTRNSTSVPKPAPQPYTFPASLSTINFDEFSPMLLPSGQISNQALALAPSSAPVLAQTMVPSSAMVPLAQPPAPAPVLTPGPPQSLSAPVPKSTQAGEGTLSEALLHLQFDADEDLGALLGNSTDPGVFTDLASVDNSEFQQLLNQGVSMSHSTAEPMLMEYPEAITRLVTGSQRPPDPAPTPLGTSGLPNGLSGDEDFSSIADMDFSALLSQISS
Select PDB:
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMDNo data.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
